{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"44","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Time in weeks from date of first study drug administration to the date of progressive disease according to the RECIST guidelines (Response evaluation in solid tumors, version 1.0), or death due to any cause.","dispersionType":"Full Range","groups":[{"description":"AZD4877 25 mg (Intravenous (IV), 25mg weekly)","id":"OG000","title":"AZD4877"}],"paramType":"MEDIAN","populationDescription":"Of the 41 participants who received at least one dose of study medication, only 39 were evaluable for response by RECIST (excludes 2 patients who had baseline scans performed more than 28 days before dosing).","reportingStatus":"POSTED","timeFrame":"Time from the first administration of study drug to disease progression or death (maximum treatment period of 309 days (44 weeks)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Weeks"}